How Roivant Sciences Could Score Big Wins Through High-Stakes IP Battles with Pharma Giants! 

Roivant Sciences, in its most recent fiscal year-end earnings, reported a period of significant activity and progress across several fronts. The company emphasized advancements in its late-stage pipeline, particularly in its anti-FcRn franchise and developments in brepocitinib. The fiscal year was marked by the generation of critical data from studies involving batoclimab in Myasthenia Gravis and CIDP, as well as anticipation for pivotal data from brepocitinib in dermatomyositis, which could lead to novel treatments with significant lead-time advantages.